Skip to content
OpenCapital
Get started

King Pharmaceuticals KG Q1 2026 earnings

Reported May 8, 2026 · Before market open

Revenue$10.2MMiss by $336.3MDiluted EPS-$1.34
Revenue estimate$346.5M

Next report

Aug 7, 2026 (In 3 weeks)
Revenue estimate$338.6M

Financials

Q1 2026

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M—
Total equity$121.4M+2,773%
Total assets$964.2M—

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$81.92M—
Enterprise value$196.43M—
P/E1.4×—
P/S1.9×—

Returns & leverage

See full
Debt / equity1.5×—

Versus estimates

Revenue

Q1 2026$10.2MMiss by $336.3M
Q4 2025$10.2MMiss by $412.5MQ3 2025$20.3MQ2 2025$546.0K

Diluted EPS

Q1 2026-$1.34
Q4 2025-$1.06Miss by $2.26Q3 2025-$1.95Q2 2025-$0.72

Ask the moment King Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did King Pharmaceuticals report Q1 2026 earnings?
King Pharmaceuticals (KG) reported Q1 2026 earnings on May 8, 2026 before market open.
What were King Pharmaceuticals's Q1 2026 revenue and EPS?
King Pharmaceuticals reported revenue of $10.2M and diluted EPS of $-1.34 for Q1 2026.
Did King Pharmaceuticals beat estimates in Q1 2026?
Revenue missed the consensus estimate of $346.5M by $336.3M.
Where can I find King Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-032893) and the 10-Q periodic report (0001628280-26-032898) directly on SEC EDGAR. The filing index links above go to sec.gov.